GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Gross Property, Plant and Equipment

ATHA (Athira Pharma) Gross Property, Plant and Equipment : $6.61 Mil (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Gross Property, Plant and Equipment?

Athira Pharma's quarterly gross PPE declined from Mar. 2024 ($6.70 Mil) to Jun. 2024 ($6.67 Mil) and declined from Jun. 2024 ($6.67 Mil) to Sep. 2024 ($6.61 Mil).

Athira Pharma's annual gross PPE increased from Dec. 2021 ($5.74 Mil) to Dec. 2022 ($6.68 Mil) and increased from Dec. 2022 ($6.68 Mil) to Dec. 2023 ($6.77 Mil).


Athira Pharma Gross Property, Plant and Equipment Historical Data

The historical data trend for Athira Pharma's Gross Property, Plant and Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athira Pharma Gross Property, Plant and Equipment Chart

Athira Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Property, Plant and Equipment
Get a 7-Day Free Trial 0.07 3.66 5.74 6.68 6.77

Athira Pharma Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Property, Plant and Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.83 6.77 6.70 6.67 6.61

Athira Pharma Gross Property, Plant and Equipment Calculation

Property, Plant and Equipment (PPE) are the fixed assets of the company. Fixed assets are also known as non-current assets.

Property, plant, and equipment includes assets that will - in the normal course of business - neither be used up in the next year nor will become a part of any product sold to customers.

Some of the most common parts of property, plant, and equipment are:


Land
Buildings (and leasehold improvements)
Transportation equipment
Manufacturing equipment
Office equipment
Office furniture

Companies with lots of property, plant, and equipment often have special categories. For example, railroad property includes:


Track
Ties
Ballast
Bridges
Tunnels
Signals
Locomotives
Freight Cars

There is often a note in the financial statements - found in a company's 10-K - that will explain the different categories of property a company owns.

The market value of property, plant, and equipment can differ tremendously from the book value of property, plant, and equipment.

For example, when Berkshire Hathaway liquidated its textile mills, it had to pay the buyers of the company's manufacturing equipment to haul the equipment away. That property, plant, and equipment was literally worth less than zero. On the other hand, some companies own thousands of acres of land.

All property, plant, and equipment other than land is depreciated. Land is never depreciated. However, land is not marked up to market value either. Under Generally Accepted Accounting Principles (GAAP), land is shown on the balance sheet at cost.

The property, plant, and equipment line shown on the balance sheet is usually net property, plant, and equipment. This means it is the cost of the property, plant, and equipment less accumulated depreciation.


Athira Pharma  (NAS:ATHA) Gross Property, Plant and Equipment Explanation

A company with durable competitive advantage doesn't need to constantly upgrade its equipment to stay competitive. The company replaces when it wears out. On the other hand, a company without any advantages must replace to keep pace.

Difference between a company with a moat and one without is that the company with the competitive advantage finances new equipment through internal cash flows, whereas the no advantage company requires debt to finance.

Producing a consistent product that doesn't change equates to consistent profits. There is no need to upgrade plants which frees up cash for other ventures. Think Coca Cola, Johnson & Johnson etc.


Athira Pharma Gross Property, Plant and Equipment Related Terms

Thank you for viewing the detailed overview of Athira Pharma's Gross Property, Plant and Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.


Athira Pharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Executives
Mark James Litton officer: Chief Operating Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington officer: General Counsel C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Rachel Lenington officer: Chief Technology Officer C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Kevin Church officer: Vice President of Discovery 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Andrew Gengos officer: See Below 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Kelly A Romano director C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Grant Pickering director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Glenna Mileson officer: Chief Financial Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Hans Moebius officer: Chief Medical Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara director 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014